Osteoporosis Drugs Market By Share, Size and Forecast 2028|TechSci Research

Summary

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 16.09 Billion
CAGR (2023-2028)	5.73%
Fastest Growing Segment	Online Pharmacy
Largest Market	North America

Market Overview

Global Osteoporosis Drugs Market has valued at USD 16.09 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.73% through 2028. Osteoporosis is a disease characterized by the deterioration of bone tissues and strength. Diagnosis involves the use of various scans, including X-ray, computed tomography (CT), and magnetic resonance imaging (MRI). Currently, a wide range of drugs are available in different formulations, from regular tablets to intravenous (IV) infusions, to alleviate the symptoms of osteoporosis. These medications help restore the balance between resorption and formation, repair microscopic bone defects, reduce the risk of fractures, and enhance overall muscle strength in patients.

Key Market Drivers

Increasing Incidences of Osteoporosis

The increasing incidences of osteoporosis are undeniably contributing to a significant rise in the demand for osteoporosis drugs. Osteoporosis, characterized by weakened bones that are more prone to fractures, primarily affects the elderly population, especially postmenopausal women. Osteoporosis disproportionately affects women, especially postmenopausal women, due to hormonal changes that accelerate bone loss. As the female population grows, so does the prevalence of osteoporosis, which directly fuels the demand for drugs designed to manage and mitigate the condition.

Growing Clinical Trials and Rising Geriatric Population

Osteoporosis is most common in the elderly, particularly postmenopausal women. With a globally aging population, there is a substantial increase in the number of individuals at risk of developing osteoporosis. As people age, their bone density naturally decreases, making osteoporosis more prevalent among seniors. - There is a significant and growing market opportunity in the field of research and development, as key players continue to invest in enhancing their technological capabilities. These investments are aimed at driving novel advancements that can meet the evolving needs of various industries. Additionally, the market is being influenced by the rising prevalence of osteoporosis, a condition characterized by weakened bones. This trend is creating a demand for innovative solutions that can effectively address the challenges posed by osteoporosis.

For instance, according to a report by the World Health Organization in 2022, the global population of individuals aged 60 and older is projected to reach one in six by the year 2030. By this point, the number of people over the age of 60 is expected to reach a staggering 1.4 billion, marking a significant increase from the 1 billion recorded in 2020. Looking further ahead, the number of individuals aged 60 or older is projected to double by 2050, reaching a staggering 2.1 billion. Furthermore, between 2020 and 2050, the number of people aged 80 or older is expected to triple, reaching a noteworthy 426 million.

These statistics paint a vivid picture of the demographic changes that are taking place globally, underscoring the need for innovative solutions that can cater to the needs of an aging population. As a result, the market for products and services aimed at addressing the challenges associated with aging, such as osteoporosis, is poised for significant growth and presents a unique opportunity for businesses operating in this space.

Improved Awareness and Diagnosis

Advances in medical knowledge and diagnostic technologies have led to more accurate and earlier diagnoses of osteoporosis. Increased awareness of the disease and its potential consequences prompts individuals to seek medical intervention and treatment, driving up the demand for osteoporosis drugs.

The Growing Investments in Research and Development

The expanding body of research on osteoporosis medications, coupled with increased investments by major biopharmaceutical companies, the growing elderly population, and the emergence of innovative technologically advanced therapies, collectively drive the growth of the global osteoporosis drug market.

For instance, in April 2023, the Van Andel Research Institute published a report highlighting a significant factor that contributes to reduced bone density. This discovery holds the potential for developing more efficient medications with fewer adverse effects for women with osteoporosis. The global osteoporosis drugs market is witnessing significant expansion due to increasing research studies on osteoporosis drugs, rising regulatory approvals for innovative products, a growing geriatric population, and advancements in technologically advanced therapies.

In the upcoming years, the market is poised to grow as a result of increased investment in research and development by biotechnology and pharmaceutical companies. For example, in October 2020, the Italian pharmaceutical regulatory body approved human clinical studies for the osteoporosis medicine raloxifene. Researchers believe that this treatment may also have potential benefits for individuals with COVID-19, improving their well-being and reducing contagion. Positive outcomes from clinical trials could lead to the development of new therapeutic options, thereby driving future market expansion. Furthermore, the increasing incidence of osteoporosis worldwide among individuals with reduced bone density is another important factor contributing to market growth. According to Osteoporosis Canada 2022, more than 2.3 million Canadians suffer from osteoporosis, with osteoporosis being responsible for 80% of fractures in adults aged 50 and older.

Download Free Sample Report

Key Market Challenges

Stringent Regulatory Environment

A stringent regulatory environment has played a role in decreasing the demand for osteoporosis drugs, primarily by impacting drug development, marketing, and access. Osteoporosis drugs, like all pharmaceuticals, must undergo rigorous clinical trials and meet stringent safety and efficacy criteria before gaining approval. These trials can be time-consuming and resource-intensive, delaying the introduction of new drugs to the market. Patients suffering from osteoporosis may not have timely access to innovative treatment options, decreasing demand for existing drugs.

Meeting regulatory requirements often entails substantial research and development costs for pharmaceutical companies. These costs can translate into higher prices for osteoporosis drugs, potentially limiting affordability and reducing patient access. Regulatory agencies, understandably, prioritize patient safety. While this is essential, the stringent safety standards can sometimes hinder the availability of certain drugs. This is particularly true if a drug shows even a remote risk of adverse effects, leading to limited demand for drugs with potential benefits.

High Costs Of Treatment

The high costs of treatment pose a significant challenge for the growth of the osteoporosis drugs market vendors. Osteoporosis, a condition characterized by weakened bones, requires long-term management to reduce pain and improve functions. However, as no therapy has the potential to reverse joint damage, patients often face life-long expenses for treating the disease and preventing symptoms using drugs. Moreover, the cost of treatments varies across regions, influenced by various health condition factors.

According to the Centers for Disease Control and Prevention (CDC), osteoporosis is the second most prevalent health condition treated globally. This widespread prevalence imposes a high financial burden not only on patients but also on healthcare systems. The substantial costs associated with managing osteoporosis are expected to hinder the growth of the osteoporosis drugs market during the forecast period.

It is crucial to address the issue of high treatment costs and explore innovative solutions to make osteoporosis drugs more accessible and affordable for patients worldwide. By doing so, we can alleviate the financial burden on individuals and healthcare systems while ensuring effective management of this prevalent health condition.

Key Market Trends

Precision Medicine

The development of personalized osteoporosis treatments tailored to an individual's genetic and lifestyle factors is on the horizon. This approach aims to maximize the effectiveness of therapies while minimizing side effects. Personalized medicine allows for more precise risk assessment. Patients with a family history of osteoporosis or specific genetic predispositions can be identified early, enabling proactive interventions to prevent bone loss and fractures. Personalized medicine may involve adjusting medication dosages based on an individual's genetic and metabolic characteristics. This ensures that patients receive the right amount of medication to achieve therapeutic benefits while minimizing the risk of side effects.

Patients undergoing personalized treatment receive ongoing monitoring and follow-up care. This proactive approach allows healthcare providers to assess treatment efficacy and make adjustments as needed, ensuring that the patient's bone health remains optimized.

Novel Drug Targets

Ongoing research is uncovering new molecular targets for osteoporosis drugs. These targets may include specific proteins or cellular pathways involved in bone metabolism, offering opportunities for innovative drug development. With a deeper understanding of the molecular mechanisms underlying bone metabolism, researchers can design drugs that specifically target these mechanisms. This includes the development of small molecules, antibodies, and other therapeutic agents tailored to interact with specific proteins or signaling pathways.

Ongoing research is uncovering a wealth of knowledge about the molecular targets involved in osteoporosis. These discoveries hold the potential to revolutionize the development of osteoporosis drugs, leading to more effective, targeted, and personalized treatments that improve bone health and reduce the risk of fractures in individuals living with this condition.

Segmental Insights

Route of Administration Insights

Based on the route of administration, the market for osteoporosis is segmented into oral, injectable, and others. Oral drugs are known for being cost-effective and safe, although they may have mild side effects. Rare serious effects, such as osteonecrosis of the jaw, have been reported. However, in terms of effectiveness, oral medications have proven successful in treating osteoporosis. For instance, alendronate (Fosamax) has shown its ability to reduce the risk of hip fractures by 50%. Notably, patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences. This preference highlights the importance of oral medications in the management of osteoporosis.

Injectable drugs like denosumab (Prolia) have emerged as highly effective options with immediate effects for treating osteoporosis. These medications, while generally safe, do come with the potential for mild side effects. Additionally, there is a rare but serious risk of osteonecrosis of the jaw (ONJ) associated with their use. Despite these considerations, the patent protection granted to these injectable drugs ensures exclusivity, allowing manufacturers to set higher prices. To further maximize their market presence, manufacturers heavily invest in marketing efforts, which in turn influence prescribing patterns. Interestingly, brand loyalty among patients continues to drive the Osteoporosis Drugs Market, even in the presence of alternative treatment options.

Drug Type Insights

In terms of Drug Type, the bisphosphonates accounted for a significant share of the osteoporosis drugs market in 2022. This can be attributed to the increased investment in research and development of advanced novel bisphosphonates drugs by major players in the pharmaceutical industry. Moreover, bisphosphonates are widely prescribed drugs for the treatment of osteoporosis, which further drives the growth of the market.

On the other hand, the rank ligand inhibitors segment is projected to witness the fastest growth rate during the forecast period. This is primarily due to the fact that these drugs are specifically used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells expressing its receptor, RANK. As a result, the inhibition of the RANKL-RANK pathway serves as an ideal treatment approach for bone metastasis. The detailed understanding and utilization of these drug types contribute to the advancement of osteoporosis treatment, ultimately improving the quality of life for patients affected by this condition.

Download Free Sample Report

Regional Insights

Region wise, North America accounted for the major share in 2018 and is expected to continue this trend. This can be attributed to the easy availability of osteoporosis drugs in the region, which has contributed to its growth. Additionally, the surge in the incidence of osteoporosis has further fueled the demand for these drugs.

On the contrary, Asia-Pacific is anticipated to register the fastest growth during the forecast period. This can be attributed to the increasing awareness regarding the use of osteoporosis drugs in the region. Furthermore, the constantly evolving life science industry has been a key driver of the market's growth in developing economies such as India, China, and Malaysia. The presence of a robust market and the focus on research and development activities have propelled the growth of the osteoporosis drugs market in these regions.

Recent Developments

In May 2023, a recent real-world study involving nearly half a million postmenopausal women with osteoporosis in the U.S. Medicare program revealed that Prolia (denosumab) injection demonstrated a reduction in fracture risk when compared to oral alendronate, a commonly prescribed bisphosphonate medication. Furthermore, the long-term use of Prolia was associated with significant decreases in the risk of fractures.
In August 2021, Enzene Biosciences Ltd obtained Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its biosimilar drug, denosumab. This particular drug is indicated for the treatment of osteoporosis in adults.
In January 2021, Livogiva, an osteoporosis medicine, was launched in Europe by Theramex, a pharmaceutical company headquartered in London.

Key Market Players

Eli Lilly and Company
Pfizer Inc.
F. Hoffmann-La Roche
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc.
Novartis International AG
Merck & Co. Inc.
Amgen Inc.
Radius Health Inc.
Actavis PLC

By Drug Type	By Route of Administration	By Application	By Distribution Channel	By Region
Parathyroid Hormone Therapy Bisphosphonates Calcitonin Selective Estrogen Receptor Modulators Other Drug Types	Oral Injectables Others	Primary Osteoporosis Secondary Osteoporosis	Hospital Pharmacy Retail Pharmacy Online Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Drug Type:

o Parathyroid Hormone Therapy

o Bisphosphonates

o Calcitonin

o Selective Estrogen Receptor Modulators

o Other Drug Types

Osteoporosis Drugs Market, By Route of Administration:

o Oral

o Injectables

o Others

Osteoporosis Drugs Market, By Application:

o Primary Osteoporosis

o Secondary Osteoporosis

Osteoporosis Drugs Market, By Distribution Channel:

o Hospital Pharmacy

o Retail Pharmacy

o Online Pharmacy

Osteoporosis Drugs Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Kuwait

§ Turkey

§ Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

Global Osteoporosis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Osteoporosis Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validations

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteoporosis Drugs Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types)

5.2.2. By Route of Administration (Oral, Injectables, Others)

5.2.3. By Application (Primary Osteoporosis and Secondary Osteoporosis)

5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

5.2.5. By Region

5.2.6. By Company (2022)

5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Type

6.2.2. By Route Of Administration

6.2.3. By Application

6.2.4. By Distribution Channel

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Osteoporosis Drugs Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Drug Type

6.3.1.2.2. By Route Of Administration

6.3.1.2.3. By Application

6.3.1.2.4. By Distribution Channel

6.3.2. Canada Osteoporosis Drugs Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Drug Type

6.3.2.2.2. By Route Of Administration

6.3.2.2.3. By Application

6.3.2.2.4. By Distribution Channel

6.3.3. Mexico Osteoporosis Drugs Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Drug Type

6.3.3.2.2. By Route Of Administration

6.3.3.2.3. By Application

6.3.3.2.4. By Distribution Channel

7. Europe Osteoporosis Drugs Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. Drug Type

7.2.2. By Route Of Administration

7.2.3. By Application

7.2.4. By Distribution Channel

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Osteoporosis Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Type

7.3.1.2.2. By Route Of Administration

7.3.1.2.3. By Application

7.3.1.2.4. By Distribution Channel

7.3.2. United Kingdom Osteoporosis Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Type

7.3.2.2.2. By Route Of Administration

7.3.2.2.3. By Application

7.3.2.2.4. By Distribution Channel

7.3.3. Italy Osteoporosis Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecasty

7.3.3.2.1. By Drug Type

7.3.3.2.2. By Route Of Administration

7.3.3.2.3. By Application

7.3.3.2.4. By Distribution Channel

7.3.4. France Osteoporosis Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Type

7.3.4.2.2. By Route Of Administration

7.3.4.2.3. By Application

7.3.4.2.4. By Distribution Channel

7.3.5. Spain Osteoporosis Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Drug Type

7.3.5.2.2. By Route Of Administration

7.3.5.2.3. By Application

7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Osteoporosis Drugs Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. Drug Type

8.2.2. By Route Of Administration

8.2.3. By Application

8.2.4. By Distribution Channel

8.2.5. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Osteoporosis Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Type

8.3.1.2.2. By Route Of Administration

8.3.1.2.3. By Application

8.3.1.2.4. By Distribution Channel

8.3.2. India Osteoporosis Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Type

8.3.2.2.2. By Route Of Administration

8.3.2.2.3. By Application

8.3.2.2.4. By Distribution Channel

8.3.3. Japan Osteoporosis Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Type

8.3.3.2.2. By Route Of Administration

8.3.3.2.3. By Application

8.3.3.2.4. By Distribution Channel

8.3.4. South Korea Osteoporosis Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Type

8.3.4.2.2. By Route Of Administration

8.3.4.2.3. By Application

8.3.4.2.4. By Distribution Channel

8.3.5. Australia Osteoporosis Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Type

8.3.5.2.2. By Route Of Administration

8.3.5.2.3. By Application

8.3.5.2.4. By Distribution Channel

9. South America Osteoporosis Drugs Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. Drug Type

9.2.2. By Route Of Administration

9.2.3. By Application

9.2.4. By Distribution Channel

9.2.5. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Osteoporosis Drugs Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Type

9.3.1.2.2. By Route Of Administration

9.3.1.2.3. By Application

9.3.1.2.4. By Distribution Channel

9.3.2. Argentina Osteoporosis Drugs Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Type

9.3.2.2.2. By Route Of Administration

9.3.2.2.3. By Application

9.3.2.2.4. By Distribution Channel

9.3.3. Colombia Osteoporosis Drugs Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Type

9.3.3.2.2. By Route Of Administration

9.3.3.2.3. By Application

9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Osteoporosis Drugs Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. Drug Type

10.2.2. By Route Of Administration

10.2.3. By Application

10.2.4. By Distribution Channel

10.2.5. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Osteoporosis Drugs Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Type

10.3.1.2.2. By Route Of Administration

10.3.1.2.3. By Application

10.3.1.2.4. By Distribution Channel

10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Type

10.3.2.2.2. By Route Of Administration

10.3.2.2.3. By Application

10.3.2.2.4. By Distribution Channel

10.3.3. UAE Osteoporosis Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Type

10.3.3.2.2. By Route Of Administration

10.3.3.2.3. By Application

10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. Global Osteoporosis Drugs Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview

15.2. Service Offerings

15.3. Recent Developments

15.4. Key Personnel

15.5. SWOT Analysis

15.5.1. Eli Lilly and Company

15.5.2. Pfizer Inc.

15.5.3. F. Hoffmann-La Roche

15.5.4. Teva Pharmaceutical Industries Ltd.

15.5.5. GlaxoSmithKline plc.

15.5.6. Novartis International AG

15.5.7. Merck & Co. Inc.

15.5.8. Amgen Inc.

15.5.9. Radius Health Inc.

15.5.10. Actavis PLC

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Osteoporosis Drugs Market in 2022?

The market size of the Global Osteoporosis Drugs Market was estimated to be USD 16.09 Billion in 2022.

Which was the dominant segment by route of administration in the Global Osteoporosis Drugs Market in 2022?

In terms of route of administration, the oral segment holds the largest market share in osteoporosis drugs. This is primarily due to the wide availability of oral medications in the market. On the other hand, the injectable segment is projected to experience the highest compound annual growth rate (CAGR) during the forecast period. This can be attributed to factors such as increasing demand for drugs with improved bioavailability and rapid mode of action.

Which is the dominant region in the Global Osteoporosis Drugs Market?

North America is expected to hold a significant market share during the forecast period due to factors such as the rising number of osteoporosis patients, well-established healthcare facilities, presence of key players, and availability of branded drugs in the region. On the other hand, the Asia Pacific market is projected to witness substantial growth at a considerable CAGR in the coming years. This growth can be attributed to the geographical expansion of market leaders, increased investment in R&D, and efforts to provide branded drugs and generic treatments at an affordable cost in the region.

What are the major drivers for the Global Osteoporosis Drugs Market?

Rise in prevalence of osteoporosis and surge in geriatric population across the globe are the major drivers for the Global Osteoporosis Drugs Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Osteoporosis Drugs Market to Grow with a CAGR of 5.73% through 2028

Sep, 2023

Increasing incidences of osteoporosis and the growing investments in research & development by biopharmaceutical companies is expected to drive the Global Osteoporosis Drugs growth in the forecast pe

Buy Now